NR1H4 and Disorder of lipid metabolism: In vivo studies have shown that disrupting the gut microbiota perturbs bile acid metabolism, inhibits FXR signaling, and consequently triggers glucose and lipid metabolic disorders, whereas supplementation with FXR agonists can significantly ameliorate these abnormalities (71).